In vitro drug-induced cytotoxicity predicts clinical response to high-dose chlorambucil in B-cell chronic lymphocytic leukemia.
Callea
V
V
Stelitano
C
C
Callea
I
I
Console
G
G
Brugiatelli
M
M
Morabito
F
F
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use; D002470:Cell Survival; D002699:Chlorambucil / Q000494:pharmacology* / Q000627:therapeutic use; D004396:Coloring Agents; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015999:Multivariate Analysis; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D012074:Remission Induction; D013778:Tetrazolium Salts; D013844:Thiazoles; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D004396:Coloring Agents; D013778:Tetrazolium Salts; D013844:Thiazoles; D002699:Chlorambucil; C022616:thiazolyl blue